Summary
More frequently reported side effects include: increased serum potassium. Continue reading for a comprehensive list of adverse effects.
Applies to nebivolol / valsartan: oral tablet.
Warning
Oral route (Tablet)
When pregnancy is detected, discontinue nebivolol/valsartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Serious side effects
Along with its needed effects, nebivolol / valsartan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nebivolol / valsartan:
Incidence not known
- Blurred vision
- chest pain or tightness
- confusion
- decreased urine output
- difficult breathing
- dilated neck veins
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- extreme fatigue
- irregular breathing
- irregular heartbeat
- nausea or vomiting
- nervousness
- numbness or tingling in the hands, feet, or lips
- stomach pain
- sweating
- swelling of the face, fingers, feet, or lower legs
- trouble breathing
- unusual tiredness or weakness
- weakness or heaviness of the legs
- weight gain
For Healthcare Professionals
Applies to nebivolol / valsartan: oral tablet.
Cardiovascular
Frequency not reported: Hypotension
Nebivolol:
Postmarketing reports: Atrioventricular block (both second and third degree), myocardial infarction, Raynaud's phenomenon, peripheral ischemia/claudication
Valsartan:
Postmarketing reports: Vasculitis[Ref]
Dermatologic
Rare (0.01% to 0.1%): Angioedema
Nebivolol:
Postmarketing reports: Pruritus, psoriasis, various rashes, various skin disorders, urticaria, allergic vasculitis
Valsartan:
Postmarketing reports: Angioedema, alopecia, bullous dermatitis[Ref]
Gastrointestinal
Postmarketing reports: Vomiting[Ref]
Genitourinary
Postmarketing reports: Erectile dysfunction
Nebivolol:
Postmarketing reports: Thrombocytopenia
Valsartan:
Postmarketing reports: Thrombocytopenia[Ref]
Hepatic
Nebivolol:
Postmarketing reports: Abnormal hepatic function (including increased AST, ALT, and bilirubin)
Valsartan:
Postmarketing reports: Elevated liver enzymes, hepatitis
Valsartan:
Postmarketing reports: Angioedema[Ref]
Metabolic
Common (1% to 10%): Hyperkalemia
Valsartan:
Postmarketing reports: Hyperkalemia[Ref]
Nervous system
Postmarketing reports: Somnolence, syncope, vertigo
Nebivolol:
Postmarketing reports: Acute renal failure
Valsartan:
Postmarketing reports: Impaired renal function, renal failure[Ref]
Respiratory
Nebivolol:
Postmarketing reports: Acute pulmonary edema, bronchospasm[Ref]
